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background:  Renal sympathetic denervation (RSD) represents a potential treatment option for patients with resistant hypertension, but in 
some patients it is unsuccessful. Therefore, identifying patients who potentially benefit from RSD remains a major clinical challenge. Brain-
derived neurotrophic factor (BDNF) is an important modulator of synaptic plasticity and regulates the activity of the sympathetic nervous 
system (SNS). Therefore the primary aim of the present study was to evaluate whether analysis of BDNF serum levels may provide 
immediate assessment of the success of RSD.
Methods:  A total of 100 consecutive patients undergoing RSD were included in this study. A therapeutic response was defined as an 
office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous serum samples for measurement of BDNF were 
collected prior to RSD and 2 hours and 6 months after RSD.
Results:  A significant reduction in office SBP of 24.3 mmHg (SBPbaseline: 166.9 [±14.3] mmHg, p<0.001) was documented 6 months 
after RSD. BDNF levels significantly decreased 2 hours after RSD (baseline: 48.6 μg/L [IQR: 25.8;115.8] vs. 2 hours: 29.4 μg/L [IQR: 
16.8;56.9], p<0.001). There were significant differences in the extent of BDNF level changes between BP responders (fold change: -38%) 
and non-responders (fold change: -6%) 2 hours after RSD (p<0.001). Further, there was a significant correlation between acute BDNF level 
reduction and SBP reduction 6 months after RSD (r = 0.51, p=0.001).
conclusion:  This is the first study that proposes an approach for immediate assessment of successful RSD procedure by measurement 
of BDNF as a specified biomarker for synaptic activity of the SNS. Therefore, these results provide further validation of sufficient RSD and 
may make the procedure more reliable.
